286 related articles for article (PubMed ID: 26317313)
21. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
22. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
[TBL] [Abstract][Full Text] [Related]
23. Genetic predisposition to ductal carcinoma in situ of the breast.
Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
[TBL] [Abstract][Full Text] [Related]
24. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
25. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
27. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
28. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
[TBL] [Abstract][Full Text] [Related]
30. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.
Jirström K; Ringberg A; Fernö M; Anagnostaki L; Landberg G
Br J Cancer; 2003 Nov; 89(10):1920-6. PubMed ID: 14612904
[TBL] [Abstract][Full Text] [Related]
31. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
[TBL] [Abstract][Full Text] [Related]
32. [Does molecular biology play any role in ductal carcinoma in situ?].
Sakr RA
Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
[TBL] [Abstract][Full Text] [Related]
33. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
34. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
36. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
[TBL] [Abstract][Full Text] [Related]
37. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
38. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
39. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
[TBL] [Abstract][Full Text] [Related]
40. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.
Miligy IM; Toss MS; Gorringe KL; Lee AHS; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2019 May; 120(11):1075-1082. PubMed ID: 31065110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
